Roles of NKT cells in cancer immunotherapy

• Published in: Archives of pharmacal research Vol. 42; no. 7; pp. 543 - 548
• Main Authors: Bae, Eun-Ah, Seo, Hyungseok, Kim, Il-Kyu, Jeon, Insu, Kang, Chang-Yuil
• Format: Journal Article
• Language: English
• Published: Seoul Pharmaceutical Society of Korea 01.07.2019; 대한약학회
• Subjects: Animals; Humans; Immunotherapy; Medicine; Natural Killer T-Cells - immunology; Neoplasms - immunology; Neoplasms - therapy; Pharmacology/Toxicology; Pharmacy; Review; 약학; Alpha-galactosylceramide (α-GalCer); CD1d; Cancer immunotherapy; Invariant natural killer T (iNKT) cell; Tumor immunology
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-019-01139-8

Cancer immunotherapy has emerged as an effective therapeutic strategy to treat cancer. Among diverse immune populations, invariant natural killer T (iNKT) cells have shown potent antitumor activity by linking innate and adaptive immune systems. Upon activation by lipid antigens on CD1d molecules, iNKT cells rapidly produce various cytokines and trigger antitumor immunity directly or indirectly by activating other antitumor immune cells. Administration of a representative iNKT cell ligand alpha-galactosylceramide (α-GalCer) or α-GalCer-pulsed APCs effectively stimulates iNKT cells and thereby induces antitumor effects. In this review, we will introduce the biology and importance of NKT cells in antitumor immunity. Previous studies have demonstrated that iNKT cells not only activate various immune cells but also reinvigorate exhausted immune cells in the tumor microenvironment. Furthermore, we will summarize the major clinical trials utilizing iNKT-based immunotherapies.